Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Article Details

Citation

Copy to clipboard

Creese I, Burt DR, Snyder SH

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):223-6. doi: 10.1176/jnp.8.2.223.

PubMed ID

9081563 [ View in PubMed

]

Abstract

Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Triflupromazine	Dopamine D1 receptor	Protein	Humans	Yes	Antagonist	Details
Triflupromazine	Dopamine D2 receptor	Protein	Humans	Yes	Antagonist	Details